NCT04680052 2025-12-22InMINDIncyte CorporationPhase 3 Active not recruiting654 enrolled 40 charts 1 FDA
NCT01897571 2024-03-26Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCLIpsenPhase 1/2 Completed400 enrolled 22 charts 2 FDA